Investors have given Hemera Biosciences, founded by doctors and faculty members of the Tufts University School of Medicine in Boston, $3.8 million to fund the development of its macular degeneration gene therapy treatment, according to a report by The Boston Globe.
The funding is expected to finance the creation of a new drug and eventually begin a Phase I study on humans.
More Articles on Ophthalmology:
Vitra Multispot Laser System Receives FDA 510(k) Clearance
Aloha Laser Vision Offers In-Office Prescription Medication
Dr. Carey Rowan Expands Florida Practice
Recommended Live Webinar on Dec 10, 2025 12:00 PM - 1:00 PM CST